anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

222,061-222,120 of 319,975

filter-aware
24
The slide lists 10 advisors with their headshots, names, roles, and company logos.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
25
The slide uses a DNA double-helix motif to represent the company's focus on molecular diagnostics.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
26
Includes income statement items, balance sheet data, and equity structure.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
27
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
28
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
01
Slide 1
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
02
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
03
The slide uses a process-flow structure to connect the technology platform (LNCs) to a lead asset (MAT2203) and future pipeline expansion.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
04
The slide uses a Gantt-style visualization to show the development stage of various programs.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
05
The slide uses a combination of molecular diagrams and bulleted lists to explain the mechanism and benefits of the LNC technology.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Product1 hit
06
Technical scientific slide detailing the mechanism of action for a drug delivery platform.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Product1 hit
07
The LNC column is highlighted in light yellow to emphasize the company's proprietary technology.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Product1 hit
08
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Product1 hit
09
Uses authority-citation to establish urgency and market relevance.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a 'Before-After-Bridge' style logic (Characteristics - Limitations = Unlocked Potential).Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The slide uses a process flow diagram to map clinical outcomes to specific data points.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
12
This is a credibility-building slide showcasing academic validation of the company's technology.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
The slide uses a human silhouette as a central anchor to map specific clinical indications to anatomical locations.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
Focuses on patients who failed or could not tolerate standard azole or IV Amphotericin B therapies.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
15
The slide uses a timeline diagram combined with two line charts to demonstrate clinical efficacy and safety.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The slide highlights both the clinical urgency and the commercial orphan disease opportunity.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
17
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
18
The slide uses a process flow diagram to illustrate the clinical trial methodology.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
19
Uses a combination of an equation-style value proposition and a chevron-based process/timeline diagram.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
20
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
21
The slide uses a matrix-like structure to map disease areas (Infection, Inflammation, Oncology) to specific animal models and clinical indications.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
22
Data presented as a multi-panel chart comparing Uninfected, Infected Untreated, SQ Remdesivir, and Oral LNC-Remdesivir groups.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
23
The chart demonstrates high uptake efficiency of LNC-formulated oligos over time across different cell types.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
24
The chart shows dose-dependent inhibition; LNC formulations consistently outperform Taxol.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
25
The slide demonstrates that oral LNC-docetaxel is as effective as IV docetaxel with no significant side effects.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
26
The chart shows a clear dose-response relationship with increasing efficacy of the LNC formulation at 2.5, 5, and 10 nM doses.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
27
Uses a chevron-based process flow to represent maturity stages.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Why Now1 hit
28
The slide uses a grid-based timeline layout to track multiple workstreams simultaneously.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Why Now1 hit
29
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Why Now1 hit
30
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Team1 hit
31
The slide uses a mix of checkmarks for completed milestones and circular arrows for pending ones.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
01
Slide 1
Matson | Investor Presentation Deck | 14 slidesMatson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations 1 hit
02
Matson | Investor Presentation Deck | 14 slidesMatson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations 1 hit
03
Matson | Investor Presentation Deck | 14 slidesMatson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations Loop · Golden Circle1 hit
04
Includes a detailed inset map for Hawaii and a legend defining service routes and office types.Matson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
05
The slide uses a table-like layout to pair high-level strategic pillars with specific supporting bullet points.Matson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
06
Matson | Investor Presentation Deck | 14 slidesMatson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations Beat · Problem1 hit
07
Includes a map of the Port of Long Beach showing terminal locations.Matson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a circular diagram to segment the four pillars of the service offering.Matson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations 1 hit
09
Includes a map showing shipping routes between Tacoma and Alaskan ports.Matson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations 1 hit
10
Matson | Investor Presentation Deck | 14 slidesMatson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations 1 hit
11
The chart shows equity income from 2018 to 2022, with a small LTM 3Q23 bar.Matson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations 1 hit
12
The slide combines a service portfolio description with a dual-axis combo chart showing financial performance.Matson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations Beat · Business Model1 hit
13
Matson | Investor Presentation Deck | 14 slidesMatson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations 1 hit
14
Includes detailed footnotes explaining adjustments for tax benefits/expenses and calculation methodologies.Matson | Investor Presentation Deck | 14 slides · Matson
Pitch deck Investor relations 1 hit
01
Slide 1
MaxCyte | Results Presentation Deck | 25 slidesMaxCyte | Results Presentation Deck | 25 slides · MaxCyte
Conference presentation Investor relations 1 hit
02
MaxCyte | Results Presentation Deck | 25 slidesMaxCyte | Results Presentation Deck | 25 slides · MaxCyte
Conference presentation Investor relations 1 hit
03
The slide uses a three-column layout to summarize key company pillars.MaxCyte | Results Presentation Deck | 25 slides · MaxCyte
Conference presentation Investor relations Beat · Problem1 hit
04
The slide uses a timeline framework to establish company history and credibility.MaxCyte | Results Presentation Deck | 25 slides · MaxCyte
Conference presentation Investor relations Beat · Problem1 hit
05
Uses a before-after framing to position the platform as a solution to industry-wide pain points.MaxCyte | Results Presentation Deck | 25 slides · MaxCyte
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
MaxCyte | Results Presentation Deck | 25 slidesMaxCyte | Results Presentation Deck | 25 slides · MaxCyte
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The central hub is 'Accelerate Product Development', surrounded by four key pillars: Shared Momentum, Clinically-Validated Platform, Unparalleled Support, and Streamlined Regulatory Process.MaxCyte | Results Presentation Deck | 25 slides · MaxCyte
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide uses a process flow diagram to show the funnel of partnerships and clinical programs.MaxCyte | Results Presentation Deck | 25 slides · MaxCyte
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The chart shows a cumulative growth curve of partner logos over time (2017-2023).MaxCyte | Results Presentation Deck | 25 slides · MaxCyte
Conference presentation Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
10
The chart uses a stacked area format to show the composition of revenue (instruments, milestones, sales-based payments) over time.MaxCyte | Results Presentation Deck | 25 slides · MaxCyte
Conference presentation Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit